PURMX Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 13

PURMX Therapeutics General Information

Description

Developer of a silver bullet and nucleic acid drug intended for malignant pleural mesothelioma. The company creates innovative nucleic acid drugs to save patients suffering from intractable diseases and offers therapies for cancer treatment, enabling healthcare professionals with drugs using small ribonucleic acid that have become deficient in cells.

Contact Information

Website
www.purmx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1-2-3 Kasumi
  • Minami-ku
  • Hiroshima, 734-8553
  • Japan
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 1-2-3 Kasumi
  • Minami-ku
  • Hiroshima, 734-8553
  • Japan

PURMX Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PURMX Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 12-Aug-2026 Completed Clinical Trials - Phase 1
7. Early Stage VC 07-May-2024 Completed Clinical Trials - Phase 1
6. Early Stage VC (Series A) 31-May-2022 Completed Clinical Trials - Phase 1
5. Seed Round Completed Startup
4. Accelerator/Incubator 01-Jul-2021 Completed Startup
3. Accelerator/Incubator Completed Startup
2. Accelerator/Incubator Completed Startup
1. University Spin-Out 27-Jan-2021 Completed Startup
To view PURMX Therapeutics’s complete valuation and funding history, request access »

PURMX Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view PURMX Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

PURMX Therapeutics Patents

  • 24

    Total Documents Applications and Grants

  • Total Patents Families

  • 16

    Granted

  • 8

    Pending

  • Expiring in next 12 mo

PURMX Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
ES-2956776-T3 Pharmaceutical composition comprising mirna-3140 for use in the treatment of cancer Active 09-Nov-2017
EP-3708173-B1 Pharmaceutical composition comprising mirna-3140 for use in treating cancer Active 09-Nov-2017
EP-3708173-C0 Pharmaceutical composition comprising mirna-3140 for use in treating cancer Active 09-Nov-2017
EP-4265725-A2 Pharmaceutical composition comprising mirna-3140 for use in treating cancer Pending 09-Nov-2017
EP-4265725-A3 Pharmaceutical composition comprising mirna-3140 for use in treating cancer Pending 09-Nov-2017 A61K31/713
To view PURMX Therapeutics’s complete patent history, request access »

PURMX Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PURMX Therapeutics Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
FRONTEO Corporation Minority
Keio Innovation Initiative Venture Capital Minority
Yokohama Capital Venture Capital Minority
Hiroshima Venture Capital Venture Capital Minority
Mitsubishi UFJ Capital Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Ready to get started?

Request a free trial

PURMX Therapeutics FAQs

  • When was PURMX Therapeutics founded?

    PURMX Therapeutics was founded in 2021.

  • Where is PURMX Therapeutics headquartered?

    PURMX Therapeutics is headquartered in Hiroshima, Japan.

  • What is the size of PURMX Therapeutics?

    PURMX Therapeutics has 10 total employees.

  • What industry is PURMX Therapeutics in?

    PURMX Therapeutics’s primary industry is Drug Discovery.

  • Is PURMX Therapeutics a private or public company?

    PURMX Therapeutics is a Private company.

  • What is PURMX Therapeutics’s current revenue?

    The current revenue for PURMX Therapeutics is .

  • How much funding has PURMX Therapeutics raised over time?

    PURMX Therapeutics has raised $8.89M.

  • Who are PURMX Therapeutics’s investors?

    FRONTEO, Keio Innovation Initiative, Yokohama Capital, Hiroshima Venture Capital, and Mitsubishi UFJ Capital are 5 of 13 investors who have invested in PURMX Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process